Single chest drain versus two drains after esophagectomy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares outcomes for patients undergoing open esophagectomy who receive either a single pleural drain or the conventional two chest drains. Participants treated at the Khyber Teaching Hospital will receive one of the two drainage approaches during surgery and be followed for postoperative outcomes. Key outcomes include pain, mobility, pleural fluid accumulation, need for additional drainage, and other complications. The trial includes all consenting adults having open esophagectomy for carcinoma and excludes those operated for benign disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients undergoing open esophagectomy for carcinoma of esophagus

Exclusion Criteria:

* Non consenting individuals esophagectomy for benign disease

Where it's running

• Khyber teaching hospital
  Peshawar, Khyberpukhtunkhwa, Pakistan Recruiting

Study contacts

• Study coordinator: Saeed Sarwar, MBBS
• Email: saeedkmc2020@gmail.com
• Phone: +923420973863

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• Testing ctDNA to detect minimal residual disease in GI cancers

  This study tests whether circulating tumor DNA can reveal minimal residual disease or early relapse in patients with esophageal, gastric, or pancreatic cancer who are receiving neoadjuvant or perioperative treatment.

  Recruiting Masaryk Memorial Cancer Institute · Brno · NCT07660627

• Upfront Chemoradiation With Consolidation Chemotherapy for Localized Esophageal Adenocarcinoma

  This study tests adding consolidative chemotherapy after chemoradiation to see if it better controls the cancer for people with localized esophageal adenocarcinoma who are candidates for chemoradiation.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT07603375

• DISP-10 for advanced colorectal, gastric, and esophageal cancers

  This trial will test a one-time combination of an engineered adenovirus (DV-10) and BCMA-directed CAR T cells (ide-cel) in adults with advanced colorectal, gastric, or esophageal cancers.

  Recruiting at 6 sites Phase 1 Dispatch Biotherapeutics · Duarte, California and 6 other locations · NCT07544589

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.